Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wallin, A; Alladi, S; Black, SE; Chen, C; Greenberg, SM; Gustafson, D; Isaacs, JD; Jokinen, H; Kalaria, R; Mok, V; Pantoni, L; Pasquier, F; Roman, GC; Rosenberg, GA; Schmidt, R; Smith, EE; Hainsworth, AH.
What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
Cereb Circ Cogn Behav. 2022; 3: 100044
Doi: 10.1016/j.cccb.2022.100044
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Schmidt Reinhold
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- •Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.